Tarsus Pharmaceuticals, Inc. TARS Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s retained earnings?
- Tarsus Pharmaceuticals, Inc. (TARS) reported retained earnings of -$433.6M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s retained earnings changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s retained earnings decreased by 12.5% year-over-year, from -$385.33M to -$433.6M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s retained earnings has grown at a 67.0% compound annual growth rate (CAGR), from -$32.85M to -$426.63M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.